Moon Surgical Expands Leadership Team to Accelerate Maestro Robot Commercialization

Moon Surgical, a rising challenger in the surgical robotics market, has announced the addition of three key executives to its leadership team. This strategic move aims to support the company's ambitious plans for the commercialization of its Maestro soft tissue robot system in the United States and Europe.

New Executive Appointments Bolster Commercialization Efforts

The company has welcomed Jonathan Conta as Chief Marketing Officer, Jeff Semone as Chief Quality and Regulatory Officer, and Jeff Driggs as President of U.S. Sales. These appointments come at a crucial juncture for Moon Surgical as it transitions from a limited market release to a broader commercial rollout of its Maestro platform.

Jonathan Conta brings over 16 years of experience from Intuitive Surgical, where he oversaw marketing and product functions across both multiport and single-port platforms. Jeff Semone, previously leading global quality and regulatory teams at Siemens Healthineers and Varian Medical Systems, will ensure Moon Surgical's compliance with industry standards. Jeff Driggs, joining from ConMed where he led sales for the AirSeal platform, also brings valuable experience from leadership positions at Intuitive Surgical.

Anne Osdoit, Moon Surgical's CEO and partner at Sofinnova Partners, emphasized the significance of these additions, stating, "These additions come at a pivotal moment for Moon Surgical. Their contributions position us to meet growing demand for Maestro and support our next stage of global expansion."

Maestro System Gains Traction in Surgical Procedures

The Maestro soft tissue system has demonstrated impressive adoption rates since its limited launch a year ago. Moon Surgical reports that the robot has been used in over 1,600 procedures worldwide, with 1,400 of these surgeries performed in just the past year. This rapid uptake underscores the platform's versatility, having supported 60 different types of minimally invasive surgeries across various specialties.

Moon Surgical received FDA clearance for a non-commercial version of the Maestro system in late 2022, followed by approval to market the commercial version in June 2024. The company, which maintains offices in Paris and San Francisco, is positioning its platform as a valuable asset for high-volume outpatient care, emphasizing its adaptability across surgical specialties.

Backed by prominent investors including Sofinnova Partners and the venture capital arms of Nvidia and Johnson & Johnson, Moon Surgical is part of a growing cohort of surgical robot developers challenging the dominance of market leader Intuitive Surgical. As the company prepares for expanded commercialization, the addition of experienced leadership from established players in the medical device industry signals Moon Surgical's commitment to capturing a significant share of the burgeoning surgical robotics market.